Whether to target single or multiple CDKs for therapy? That is the question

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cell cycle progression in normal mammalian cells is regulated by cyclin-dependent kinases (CDKs) and cyclins.
• Malignant transformation often involves the malfunction of this regulatory apparatus, leading to uncontrolled cell proliferation.
• Constitutive activation of CDK-cyclin complexes, due to loss of CDK inhibitors (e.g., p16INK4A, p27Kip1) and tumor suppressors (e.g., p53, pRb), drives cancer's high mitotic potential.

Purpose of the Study:

• To critically assess the therapeutic advantages and disadvantages of pan-specific and highly selective CDK inhibitors.
• To explore the potential of pharmacological intervention targeting cell cycle regulators in cancer treatment.
• To categorize CDK inhibitors based on their pharmacological action (broad-spectrum, pan-specific, selective).

Main Methods:

• Review of existing literature on CDK inhibitors and their mechanisms of action.
• Classification of CDK inhibitors based on their pharmacological properties.
• Critical analysis of the benefits and drawbacks of different classes of CDK inhibitors in cancer therapy.

Main Results:

• Multiple classes of CDK inhibitors have been developed over the past two decades.
• CDK inhibitors can be broadly categorized as broad-spectrum unspecific, pan-specific, or highly selective antagonists.
• The review critically evaluates the therapeutic potential and limitations of both pan-specific and selective CDK inhibitors.

Conclusions:

• Targeting cell cycle regulation via CDK inhibition presents a promising therapeutic strategy for cancer.
• The choice between pan-specific and highly selective CDK inhibitors involves a trade-off between efficacy and specificity.
• Further assessment is needed to optimize the use of CDK inhibitors in clinical cancer treatment.